These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22964634)

  • 1. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
    Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
    Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
    Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
    Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.
    Woodfield GW; Chen Y; Bair TB; Domann FE; Weigel RJ
    Genes Chromosomes Cancer; 2010 Oct; 49(10):948-62. PubMed ID: 20629094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFAP2C regulates carbonic anhydrase XII in human breast cancer.
    Franke CM; Gu VW; Grimm BG; Cassady VC; White JR; Weigel RJ; Kulak MV
    Oncogene; 2020 Feb; 39(6):1290-1301. PubMed ID: 31636386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
    Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
    Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
    Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
    Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer.
    Min SY; Kim HS; Jung EJ; Jung EJ; Jee CD; Kim WH
    Anticancer Res; 2012 Aug; 32(8):3169-75. PubMed ID: 22843889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
    Woodfield GW; Horan AD; Chen Y; Weigel RJ
    Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
    Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W
    Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
    De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
    Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
    David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
    Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation: involvement of Sp3 and a methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells.
    Wang G; Wei LN; Loh HH
    J Biol Chem; 2003 Oct; 278(42):40550-6. PubMed ID: 12890683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.
    Wu Y; Alvarez M; Slamon DJ; Koeffler P; Vadgama JV
    BMC Cancer; 2010 Feb; 10():32. PubMed ID: 20132554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
    You Y; Yang W; Wang Z; Zhu H; Li H; Lin C; Ran Y
    Cell Oncol (Dordr); 2013 Jul; 36(4):323-31. PubMed ID: 23740091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
    Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
    PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells.
    Xiang T; Fan Y; Li C; Li L; Ying Y; Mu J; Peng W; Feng Y; Oberst M; Kelly K; Ren G; Tao Q
    Oncotarget; 2016 Oct; 7(43):70924-70935. PubMed ID: 27708215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.